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Abstract
Background Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can 
enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the 
sodium channel current, and acts as a positive allosteric modulator of  GABAA receptors, binding at a non-benzodiazepine site.
Objective We assessed the efficacy and safety of adjunctive cenobamate for the treatment of focal-onset seizures in adult 
patients with epilepsy using meta-analytical techniques.
Methods We systematically searched (May, week 4, 2020) MEDLINE (accessed by PubMed), the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), and the US National Institutes of Health Clinical Trials Registry (http://www.clini 
caltr ials.gov). There were no date limitations or language restrictions. Randomized, placebo-controlled, single or double-
blinded, add-on trials of cenobamate in adult patients with uncontrolled focal-onset seizures were identified. Main outcomes 
included the proportion of patients with ≥ 50 and 100% reduction in seizure frequency during the maintenance treatment 
period compared with baseline and the incidence of treatment withdrawal and adverse events (AEs). Risk ratio (RR) with 
95% confidence interval (CI) was estimated for each outcome.
Results Two trials were included, overall enrolling 659 patients (442 for the add-on cenobamate group and 217 for the 
add-on placebo group). Seizure frequency reduction by at least 50% occurred during the maintenance phase in 50.1% of the 
patients randomized to cenobamate and 23.5% of the placebo-treated participants (RR 2.18, 95% CI 1.67–2.85; p < 0.001). 
The pooled estimated RR to achieve seizure freedom for the cenobamate group in comparison with placebo was 3.71 (95% 
CI 1.93–7.14; p < 0.001). Withdrawal from randomized treatment occurred in 16.7 and 11.1% of participants receiving 
cenobamate and placebo, respectively (RR 1.34, 95% CI 0.85–2.09; p = 0.205). Treatment was discontinued due to AEs in 
12.2 and 4.1% of the patients in the active and control arms (RR 2.27, 95% CI 1.08–4.79; p = 0.031). AEs were reported in 
76.9 and 66.8% of the patients during treatment with cenobamate and placebo (RR 1.14, 95% CI 1.02–1.26; p = 0.021). The 
cenobamate-associated AEs included somnolence, dizziness, fatigue, balance disorder, and diplopia.
Conclusions Adjunctive cenobamate in adult patients with uncontrolled focal-onset seizures is associated with a greater 
reduction in seizure frequency and a higher rate of AEs than placebo.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 3-020-00759 -9) contains 
supplementary material, which is available to authorized users.
 * Simona Lattanzi 
 alfierelattanzisimona@gmail.com
Extended author information available on the last page of the article
Key Points 
Cenobamate is a novel tetrazole-derived carbamate 
compound.
Cenobamate acts as a modulator of voltage-gated sodium 
channels and GABA currents.
Adjunctive cenobamate reduces the frequency of focal 
seizures in patients with uncontrolled epilepsy.
The most common adverse events include somnolence, 
dizziness, fatigue, balance disorder, and diplopia.
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1 Introduction
With an estimated incidence of about 80 cases per 100,000 
people and a prevalence of 5–10 cases per 1000 people, epi-
lepsy affects approximately 70 million people worldwide 
[1, 2]. The management of epilepsy is mainly symptomatic. 
Although the majority of patients with epilepsy reaches sus-
tained seizure control, seizures remain uncontrolled in more 
than one third of the cases [3–6]. Uncontrolled epilepsy is 
often disabling, with patients experiencing significant psy-
chological and social dysfunction, reduced educational and 
employment prospects, impaired quality of life, and risk of 
premature death [7, 8]. Despite the increased availability of 
antiseizure medications (ASMs) over the past 25 years, the 
burden of treatment-resistant epilepsy has remained fairly 
stable and there is still the need for novel, more effective 
therapeutic options [9].
Cenobamate is a new ASM that has been recently 
approved by the US Food and Drug Administration for the 
treatment, and is currently being reviewed by the European 
Medicines Agency for the adjunctive treatment, of focal-
onset seizures in adults [10]. Cenobamate is a novel tetra-
zole-derived carbamate compound with one chiral center 
and is structurally different from carisbamate. Dual, com-
plementary mechanisms of action may contribute to its 
antiseizure activity [11]. Cenobamate has been shown to 
reduce neuronal excitability by enhancing the fast and slow 
inactivation of sodium channels and preferentially inhibit-
ing the persistent component of the sodium channel cur-
rent [12]. Moreover, cenobamate acts as a positive allosteric 
modulator of high affinity  GABAA receptors, binding at a 
non-benzodiazepine site [13].
This systematic review and meta-analysis aimed to assess 
the efficacy and safety of adjunctive cenobamate for the 
treatment of focal seizures in patients with epilepsy.
2  Materials and Methods
2.1  Search Strategy
The results of this systematic review and meta-analysis were 
reported according to the recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses (PRISMA) statement [14]. We systematically searched 
(May, week 4, 2020) MEDLINE (accessed by PubMed), 
the Cochrane Central Register of Controlled Trials (CEN-
TRAL), and the US National Institutes of Health Clini-
cal Trials Registry (http://www.clini caltr ials.gov) (search 
strategies are outlined in the electronic supplementary 
material [ESM]). Additional data were sought in the Drug 
Approval Package of cenobamate by the US Food and Drug 
Administration [15]. There were no date limitations or lan-
guage restrictions. The reference lists of retrieved studies 
were reviewed to identify additional reports of relevant tri-
als. The protocol was not registered previously.
2.2  Eligibility Criteria
Studies were selected when they met the following entry 
criteria: randomized, single- (masking of participants) 
or double-blinded (masking of investigator and partici-
pants), placebo-controlled, parallel-group, add-on stud-
ies with active and control arms receiving oral ceno-
bamate and matched placebo, respectively, in addition 
to the existing ASM regimen. Participants had to meet 
the following criteria: any sex, any ethnicity, adult age 
(≥ 18 years), diagnosis of focal epilepsy, and seizures 
uncontrolled by one or more concomitant ASMs at stable 
doses at the time of randomization as defined within the 
original studies.
2.3  Outcome Measures
The efficacy outcomes were the proportions of patients with 
≥ 50, ≥ 75, ≥ 90, and 100% reduction in monthly seizure fre-
quency during the maintenance treatment period compared 
with the pre-randomization baseline. The safety and toler-
ability outcomes included the proportions of participants 
who withdrew from treatment for any reason and for adverse 
events (AEs) and who experienced any AE, any treatment-
related AE, and any serious AE (SAE). AEs reported in 
at least 5% of patients in either treatment arm were also 
assessed. The effects on laboratory tests, ECG, vital signs, 
and physical and neurologic examinations were narratively 
reviewed.
2.4  Study Selection, Data Extraction 
and Assessment of the Risk of Bias
Two review authors independently assessed trials for 
inclusion and extracted the following information from 
included studies: main study author and age of publica-
tion, methodology and trial design (methods of randomi-
zation, allocation concealment and blinding, duration of 
baseline and treatment periods, dose/s of cenobamate 
tested), number and demographics of participants (age, 
sex, ethnicity, concomitant ASMs, seizure frequency dur-
ing the baseline period), and number of patients expe-
riencing any outcome per randomized group. Any disa-
greement was resolved by discussion with a third review 
author. The risk of bias of the identified studies was 
assessed following the recommendations of the Cochrane 
Collaboration [16].
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2.5  Statistical Analysis
Heterogeneity among the trials was assessed through the Chi 
squared test and the I2 statistics for heterogeneity [17, 18]. 
Provided no substantial heterogeneity was present (p > 0.10), 
results were synthesized using a fixed-effects model; if the 
probability value was ≤ 0.10, a fixed- or random-effects model 
was chosen for I2 < 40% or ≥ 40%, respectively [19–25]. We 
presented heterogeneity statistics for all analyses unless only 
one trial contributed data and heterogeneity was not applica-
ble. The modified intention-to-treat (ITT) maintenance phase 
population data (all randomized patients who had taken at least 
one dose of study drug and had any maintenance phase seizure 
data) were used for the efficacy analyses. The risk ratios (RRs) 
with 95% confidence intervals (CIs) were used as the measures 
of associations between treatment and outcomes with signifi-
cance set at p < 0.05, unless otherwise specified. Results were 
presented according to cenobamate daily dosages, where suf-
ficient data were available. Data analysis was performed using 
STATA/IC 13.1 (StataCorp LP, College Station, TX, USA).
3  Results
3.1  Results of the Search and Characteristics 
of Included Studies
Thirty-seven records were identified by database and trial 
register searching, and two trials were included in the review 
and meta-analysis [26, 27] (Fig. 1). The studies assessed 
both the efficacy and safety of cenobamate, which was added 
once daily to the pre-existing antiseizure regimen at the dos-
age of 200 mg [26] or 100, 200, and 400 mg [27]. Details 
of the studies are provided in Table 1. The studies included 
659 patients, of which 442 were randomized to add-on ceno-
bamate and 217 to add-on placebo. Characteristics of the 
participants are summarized in Table 2.
All trials used adequate methods of sequence generation 
and allocation concealment. We judged all included trials at 
low risk of performance and detection bias since blinding was 
ensured by matching placebo, and patients, investigators, and 
study personnel were all masked to the treatment assignment. 
The risks of attrition and selective reporting bias were rated low 
as patients lost to follow-up and withdrawals were documented, 
and there was no suspicion of selective outcome reporting. All 
trials were sponsored by the cenobamate manufacturer.
3.2  Proportions of Patients with ≥ 50, ≥ 75, ≥ 90 
and 100% Reduction in Baseline Seizure 
Frequency
The seizure frequency reduction by at least 50% during the 
treatment maintenance phase occurred across the trials in 
50.1% of the patients randomized to add-on cenobamate 
and 23.5% of the placebo-treated participants (RR 2.18, 
95% CI 1.67–2.85; p < 0.001) (Chi squared = 0.14, df = 1, 
p = 0.706; I2 = 0.0%]. The overall pooled estimated RRs to 
achieve 75% or more, 90% or more, and 100% reduction in 
seizure frequency for the add-on cenobamate group in com-
parison with add-on placebo were 2.25 (95% CI 1.57–3.24; 
p < 0.001) (Chi squared = 1.77, df = 1, p = 0.184; I2 = 43.4%), 
4.34 (95% CI 2.42–7.78; p < 0.001) (Chi squared = 0.47, 
df = 1, p = 0.495; I2 = 0.0%), and 3.71 (95% CI 1.93–7.14; 
p < 0.001) (Chi squared = 1.55, df = 1, p = 0.214; I2 = 35.3%) 
(Figs. 2, 3, 4, 5).
Adjunctive cenobamate at either 100, 200, or 400 mg per 
day was associated with a significantly greater decrease in 
baseline seizure frequency of 50% or more in comparison 
with the inactive treatment (Fig. 2). When given at the daily 
dosage of 200 and 400 mg, add-on cenobamate was more 
effective than placebo in reducing seizure frequency by 75% 
or more (Fig. 3) and 90% or more (Fig. 4) and achieving 
seizure freedom (Fig. 5).
3.3  Treatment Withdrawal
Across the trials, withdrawal from randomized treatment for 
any reason occurred in 16.7 and 11.1% of the participants 
receiving cenobamate and placebo, respectively (RR 1.34, 
95% CI 0.85–2.09; p = 0.205) (Chi squared = 0.44, df = 1, 
p = 0.506; I2 = 0.0%). The RRs to discontinue treatment were 
0.93 (95% CI 0.46–1.88; p = 0.837), 1.26 (95% CI 0.77–2.08; 
p = 0.357) (Chi squared = 0.28, df = 1, p = 0.595; I2 = 0.0%), 
and 2.09 (95% CI 1.17–3.71; p = 0.012) for cenobamate at 
the daily doses of 100, 200, and 400 mg, compared with 
placebo.
Treatment was discontinued due to AEs in 12.2 and 4.1% 
of patients in the active and control arms (RR 2.27, 95% CI 
1.08–4.79; p = 0.031) (Chi squared = 2.17, df = 1, p = 0.140; 
I2 = 54.0%). The corresponding RRs for cenobamate at the 
doses of 100, 200, and 400 mg/day were 2.40 (95% CI 
0.88–6.58; p = 0.089), 2.02 (95% CI 0.91–4.46; p = 0.083) 
(Chi squared = 1.71, df = 1, p = 0.191; I2 = 41.4%), and 4.48 
(95% CI 1.77–11.35; p = 0.002) (Table 3).
3.4  Adverse Events
AEs were reported in 76.9 and 66.8% of the patients dur-
ing add-on cenobamate and placebo treatment, respectively 
(RR 1.14, 95% CI 1.02–1.26; p = 0.021) (Chi squared = 0.65, 
df = 1, p = 0.420; I2 = 0.0%). Adjunctive CBD was associated 
with a higher incidence of treatment-related AEs (66.3% vs 
44.2%) compared with placebo (Table 4). The AEs signifi-
cantly associated with add-on cenobamate were somnolence, 
dizziness, fatigue, balance disorder, and diplopia (Tables 4, 
5).
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Hypersensitivity reactions were reported in four patients 
treated with cenobamate. Three cases occurred at day 1, 10, 
and 57 of treatment and were of a moderate entity, mainly 
characterized by dermatologic manifestations (reddening 
of palms and soles and itching of ears; pruritic rash and 
pyrexia; rash and facial swelling); one patient developed a 
serious case of drug reaction with eosinophilia and systemic 
symptoms (DRESS) on day 24 of treatment. Treatment was 
discontinued in all cases, and patients recovered. No deaths 
occurred during the double-blind treatment phases.
There were no clinically meaningful changes from base-
line in hematology, vital signs, physical and neurological 
examination. There was a signal for a dose-related shorten-
ing of the QT interval associated with cenobamate treatment, 
with a negative change in group mean QTcB values and an 
excess of QTcB decline > 30 ms. There was an association of 
elevation of serum potassium values > 5 meq/L (upper refer-
ence range) with cenobamate treatment—out-of-range high 
values were in excess of placebo in a dose-related distribu-
tion and the maximum value observed was 5.9 meq/L. There 
were no excursions above the critical value of 6.0 meq/L.
4  Discussion
4.1  Summary of Main Results
Randomized controlled trials provided substantial evidence 
of the efficacy of adjunctive cenobamate to treat focal-onset 
seizures in adult patients with uncontrolled epilepsy, and the 
greatest effect was observed at the dosage of 400 mg/day. 
Post-hoc analyses conducted as part of the original trials 
also provided evidence of a significant efficacy of cenoba-
mate across all assessed focal seizures, including focal aware 
with a motor component, focal with impaired awareness, 
and focal to bilateral tonic–clonic seizures, with the high-
est reduction occurring in the latest [26, 27]. The control 
of this seizure subtype is noteworthy, as persistent general-
ized tonic–clonic seizures increase the risk for sudden unex-
pected death in epilepsy [28].
A remarkable finding is the high percentage of patients 
who achieved seizure freedom during the maintenance treat-
ment phase. The seizure-free rate of 20% or higher observed 
with cenobamate compares very favorably with the rates of 
Fig. 1  Flow diagram of study 
selection process. CENTRAL 
Cochrane Central Register of 
Controlled Trials
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individual and pooled pivotal clinical studies of adjunctive 
ASMs in patients with uncontrolled focal seizures, which 
ranged from 0 to 6.5% [29, 30]. Few patients achieved 
100% seizure reduction, particularly in the placebo groups. 
Accordingly, even though the results are statistically sig-
nificant and very encouraging, some of the estimates have a 
very wide confidence interval, which does introduce uncer-
tainty regarding the magnitude of the treatment effect over 
placebo. Although no accurate comparisons can be made 
between studies carried out with different protocols at dif-
ferent times and locations, cenobamate appears as one of 
the most efficacious available drugs. Seizure freedom is 
a major target of epilepsy treatment and one of the main 
issues accountable for an independent lifestyle and favorable 
quality of life [8]. Real-life data overcoming the constraints 
of the randomized controlled trial (RCT) design will help 
to address how long patients maintain seizure control with 
cenobamate and whether freedom rates will be borne out in 
clinical practice. Mechanisms of action and potential addi-
tive or synergistic interactions of cenobamate with concomi-
tant ASMs also warrant further investigation.
The overall rates of patients withdrawing cenobamate for 
any reason and AEs were consistent with those reported with 
other available add-on ASMs [29], and a meaningful differ-
ence with placebo emerged when cenobamate was admin-
istered at the highest daily dosage. Cenobamate was gener-
ally well tolerated, with the majority of AEs rated as mild 
or moderate in severity. The most common AEs associated 
with cenobamate included typical central nervous system-
related symptoms, primarily somnolence, dizziness, and 
disturbances in gait and coordination, and their incidence 
increased with the dose and tended to abate as treatment 
was maintained. The rapid cenobamate titration of 100 mg/
week from 200 to 400 mg and the impossibility as per study 
Table 1  Characteristics of the included studies
ASM antiseizure medication, CNB cenobamate
Study Study design Main inclusion/exclusion criteria Treatment arms
Chung et al. [26] Phase II
Multicenter, multinational (India, Poland, 
Republic of Korea, US)
Parallel-group, randomized, placebo-
controlled trial:
 8-week observational baseline period
 6-week double-blind titration
 6-week double-blind maintenance phase
 Open-label extension (optional)
Aged 18–65 years
Diagnosis of treatment-resistant focal 
epilepsy
History of epilepsy for at least 2 years
At least 3 focal seizures (focal aware 
with motor component, focal impaired 
awareness, or focal to bilateral tonic–
clonic) per month, with no consecutive 
21-day seizure-free period, within the 
2 months before randomization (base-
line period)
Current treatment on a stable dose of 
1–3 ASMs for at least 12 weeks prior 
to randomization
Patients taking phenytoin or phenobarbi-
tal were excluded due to the potential 
for drug–drug interaction with CNB
Oral placebo, once daily
Oral CNB 200 mg once daily
Krauss et al. [27] Phase II
Multicenter, multinational (Australia, 
Bulgaria, Czech Republic, France, 
Germany, Hungary, Israel, Poland, 
Romania, Serbia, South Korea, Spain, 
Thailand, Ukraine, UK, US)
Parallel-group, randomized, placebo-
controlled trial:
 8-week observational baseline period
 6-week double-blind titration
 12-week double-blind maintenance 
phase
 Open-label extension (optional)
Aged 18–70 years
Diagnosis of focal epilepsy uncontrolled 
despite treatment with at least one 
ASM within the past 2 years
At least 8 focal seizures (focal aware 
with a motor component, focal 
impaired awareness, or focal to bilat-
eral tonic–clonic) with a seizure-free 
interval of < 25 days during the 8-week 
baseline assessment with at least 3 of 
these seizures occurring during each of 
the two consecutive 4-week segments 
of the baseline period
Current treatment on a stable dose of 
1–3 ASMs for at least 4 weeks before 
screening
Patients taking diazepam, phenytoin, or 
phenobarbital were excluded due to 
the potential for drug–drug interaction 
with CNB
Oral placebo, once daily
Oral CNB 100, 200, 400 mg once daily
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protocol to adjust the dose of concomitant treatments might 
have also contributed to the higher rates of AEs in the 400-
mg group. Interestingly, a somewhat higher incidence of 
AEs has been observed among patients treated with ceno-
bamate and concomitantly taking sodium channel block-
ers compared with those not taking them [26]. Definitive 
conclusions cannot be drawn as the number of patients was 
small and unbalanced between groups. Further research is 
needed to explore how the potentially unique combination 
of mechanisms of action of cenobamate may affect the toler-
ability profile according to various co-administered ASMs.
Four cases of readily identifiable hypersensitivity adverse 
reactions occurred during the RCTs, including one serious 
event of DRESS. Three of these events, including the case of 
DRESS, occurred early during treatment, at the start of the 
drug or during the titration schedule. During early clinical 
development, three confirmed cases of DRESS were also 
identified among the first 953 participants exposed to ceno-
bamate, including one fatality [31]. Cutaneous, idiosyncratic 
AEs have been reported with ASMs. Reactions are generally 
mild in severity, but serious and potentially life-threatening 
events can occur [32]. Serious skin adverse reactions includ-
ing DRESS, Stevens-Johnson syndrome (SJS), and toxic epi-
dermal necrosis (TEN) are most frequently reported with 
phenytoin, carbamazepine, lamotrigine, and phenobarbital; 
however, other ASMs have been identified to carry a signifi-
cantly elevated risk [32–34]. Notably, no cases of DRESS, 
SJS, or TEN were reported among the 1339 patients exposed 
to cenobamate in the ongoing phase III, open-label, safety 
trial (ClinicalTrials.gov identifier NCT02535091) at data 
cutoff, after a median treatment duration of 9 months [35]. 
These ad interim results suggest that the titration schedule of 
Table 2  Characteristics of the study participants
Data are presented as mean (SD) or median [IQR], unless otherwise specified
ASM antiseizure medication, CNB cenobamate, IQR interquartile range, SD standard deviation
a Number of seizures over the baseline period divided by number of days in the interval multiplied by 28
b One patient had only focal aware non-motor seizures during baseline and was randomized and treated in error
c One patient received temporary treatment with a fourth ASM
Study
Chung et al. [26] Krauss et al. [27]
CNB 200 mg/day 
(n = 113)
Placebo (n = 109) CNB 100 mg/
day (n = 108)
CNB 200 mg/day 
(n = 110)
CNB 400 mg/
day (n = 111)
Placebo (n = 108)
Age, years 36 [range: 18, 61] 38 [range: 18, 59] 39.0 (12.1) 40.9 (12.4) 39.6 (10.3) 39.6 (12.4)
Male sex, n (%) 55 (48.7) 58 (53.2) 57 (52.8) 54 (49.1) 52 (46.8) 58 (53.7)
Race
 Caucasian/White 57 (50.4) 58 (53.2) 89 (82.4) 94 (85.5) 96 (86.5) 93 (86.1)
 Asian 49 (43.4) 45 (41.3) 10 (9.3) 11 (10.0) 11 (9.9) 9 (8.3)
 Black/African 
American
3 (2.7) 2 (1.8) 4 (3.7) 3 (2.7) 1 (0.9) 4 (3.7)
 Other/unknown 4 (3.5) 4 (3.7) 5 (4.6) 2 (1.8) 3 (2.7) 2 (1.9)
Baseline seizure 
 frequencya
7.5 [range:  0b, 187] 5.5 [range: 2, 237] 9.5 [6.0–19.8] 11.0 [6.0–26.0] 9.0 [6.0–21.5] 8.4 [6.0–19.0]
Number of concomitant ASMs, n (%)
 One 19 (16.8) 12 (11.0) 25 (23.1) 39 (35.5) 24 (21.6) 27 (25.0)
 Two 53 (46.9) 52 (47.7) 48 (44.5) 47 (42.7) 62 (55.9) 54 (50.0)
 Three or more 41 (36.3) 45 (41.3) 35 (32.9)c 24 (21.8) 25 (22.6)c 27 (25.0)
Concomitant ASMs, n (%)
 Levetiracetam 51 (45.1) 53 (48.6) 47 (43.5) 48 (43.6) 50 (45.0) 41 (38.0)
 Lamotrigine 41 (36.3) 34 (31.2) 44 (40.7) 27 (24.5) 36 (32.4) 31 (28.7)
 Carbamazepine 38 (33.6) 43 (39.4) 29 (26.9) 29 (26.4) 25 (22.5) 39 (36.1)
 Oxcarbazepine 24 (21.2) 26 (23.9) 15 (13.9) 17 (15.5) 19 (17.1) 13 (12.0)
 Valproate or valproic 
acid
30 (26.5) 31 (28.4) 23 (21.3) 28 (25.5) 28 (25.2) 31 (28.7)
 Clobazam 22 (19.5) 16 (14.7) 17 (15.7) 12 (10.9) 17 (15.3) 5 (4.6)
 Lacosamide 27 (23.9) 21 (19.3)
 Topiramate 25 (22.1) 21 (19.3)
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Fig. 2  Fifty percent or greater 
reduction in baseline seizure 
frequency during the treatment 
maintenance period. a Cenoba-
mate any dose, b cenobamate 
100 mg/day, c cenobamate 
200 mg/day, d cenobamate 
400 mg/day. Risk ratios are 
from a fixed-effects model. 
CI confidence interval, CNB 
cenobamate
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Fig. 3  Seventy-five percent or 
greater reduction in baseline 
seizure frequency during the 
treatment maintenance period. 
a Cenobamate any dose, b 
cenobamate 100 mg/day, c 
cenobamate 200 mg/day, d 
cenobamate 400 mg/day. Risk 
ratios are from a fixed-effects 
model. CI confidence interval, 
CNB cenobamate
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Fig. 4  Ninety percent or greater 
reduction in baseline seizure 
frequency during the treatment 
maintenance period. a Cenoba-
mate any dose, b cenobamate 
100 mg/day, c cenobamate 
200 mg/day. d cenobamate 
400 mg/day. Risk ratios are 
from a fixed-effects model. 
CI confidence interval, CNB 
cenobamate
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Fig. 5  Seizure freedom during 
the treatment maintenance 
period. a Cenobamate any dose, 
b cenobamate 100 mg/day, 
c cenobamate 200 mg/day, d 
cenobamate 400 mg/day. Risk 
ratios are from a fixed-effects 
model. CI confidence interval, 
CNB cenobamate
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Table 3  Treatment withdrawal of adjunctive cenobamate versus placebo
Risk ratios are from a fixed-effects model
AE adverse event, CNB cenobamate, CI confidence interval
Outcome or subgroup Number of studies 
[References]
Number of events/participants (%) I2 (%) Risk ratio (95% CI) p Value
CNB Placebo
Treatment withdrawal
 Any dose 2 [26, 27] 74/442 (16.7) 24/217 (11.1) 0.0 1.34 (0.85–2.09) 0.205
 CNB 100 mg/day 1 [27] 13/108 (12.0) 14/108 (13.0) 0.93 (0.46–1.88) 0.837
 CNB 200 mg/day 2 [26, 27] 31/223 (13.9) 24/217 (11.1) 0.0 1.26 (0.77–2.08) 0.357
 CNB 400 mg/day 1 [27] 30/111 (27.0) 14/108 (13.0) 2.09 (1.17–3.71) 0.012
Treatment withdrawal due to AEs
 Any dose 2 [26, 27] 54/442 (12.2) 9/217 (4.1) 54.0 2.27 (1.08–4.79) 0.031
 CNB 100 mg/day 1 [27] 12/108 (11.1) 5/108 (4.6) 2.40 (0.88–6.58) 0.089
 CNB 200 mg/day 2 [26, 27] 19/223 (8.5) 9/217 (4.1) 41.4 2.02 (0.91–4.46) 0.083
 CNB 400 mg/day 1 [27] 23/111 (20.7) 5/108 (4.6) 0.002
Table 4  Adverse events of adjunctive cenobamate versus placebo
AE adverse event, CNB cenobamate, CI confidence interval, SAE serious adverse event
Risk ratios are from a fixed-effects model; significance set at p < 0.01
Outcome Number of studies 
[References]
Number of events/participants (%) I2 (%) Risk ratio (99% CI) p Value
CNB Placebo
Any AE 2 [26, 27] 340/442 (76.9) 115/217 (53.0) 0.0 1.14 (0.99–1.31) 0.021
Treatment-related AE 2 [26, 27] 293/442 (66.3) 96/217 (44.2) 37.2 1.46 (1.17–1.83) < 0.001
Any SAE 2 [26, 27] 24/442 (5.4) 10/217 (4.6) 0.0 0.99 (0.36–2.75) 0.978
Somnolence 2 [26, 27] 109/442 (24.7) 22/217 (10.1) 16.7 2.35 (1.31–4.24) < 0.001
Dizziness 2 [26, 27] 103/442 (23.3) 33/217 (15.2) 0.0 1.53 (0.94–2.49) 0.026
Headache 2 [26, 27] 49/442 (11.1) 20/217 (9.2) 34.5 1.27 (0.63–2.57) 0.374
Nausea 2 [26, 27] 31/442 (7.0) 6/217 (2.8) 0.0 2.98 (0.92–9.61) 0.017
Fatigue 2 [26, 27] 71/442 (16.1) 16/217 (7.4) 0.0 1.96 (0.97–3.95) 0.014
Nystagmus 2 [26, 27] 25/442 (5.7) 1/217 (0.5) 0.0 7.83 (0.91–67.64) 0.014
Balance disorder 2 [26, 27] 24/442 (5.4) 1/217 (0.5) 0.0 9.19 (1.04–80.96) 0.009
Upper respiratory infection 2 [26, 27] 18/442 (4.1) 11/217 (5.1) 47.8 0.88 (0.34–2.29) 0.721
Constipation 2 [26, 27] 21/442 (4.8) 1/217 (0.5) 0.0 6.71 (0.77–58.40) 0.024
Vomiting 2 [26, 27] 17/442 (3.8) 2/117 (0.9) 0.0 3.64 (0.60–22.27) 0.066
Urinary tract infection 1 [26] 9/113 (8.0) 2/109 (1.8) 4.34 (0.60–31.56) 0.057
Tremor 1 [26] 7/113 (6.2) 3/109 (2.8) 2.25 (0.39–12.87) 0.231
Nasopharyngitis 1 [26] 7/113 (6.2) 1/109 (0.9) 6.75 (0.44–103.73) 0.072
Diarrhea 1 [26] 6/113 (5.3) 0/109 (0.0) 12.54 (0.29–541.21) 0.084
Anxiety 1 [26] 1/113 (0.9) 6/109 (5.5) 0.16 (0.01–2.54) 0.088
Ataxia 1 [27] 13/329 (4.0) 1/108 (0.9) 4.27 (0.30–60.87) 0.160
Dysarthria 1 [27] 12/329 (3.6) 0/108 (0.0) 8.26 (0.20–335.34) 0.142
Diplopia 1 [27] 36/329 (10.9) 2/108 (1.9) 5.91 (0.93–37.56) 0.013
Fall 1 [27] 10/329 (3.0) 6/108 (5.6) 0.55 (0.15–2.01) 0.232
Back pain 1 [27] 11/329 (3.3) 3/108 (2.8) 1.20 (0.23–6.29) 0.773
Vertigo 1 [27] 10/329 (3.0) 3/108 (2.8) 1.09 (0.21–5.82) 0.890
Decreased appetite 1 [27] 10/329 (3.0) 1/108 (0.9) 3.28 (0.22–48.19) 0.254
Gait disturbance 1 [27] 16/329 (4.9) 3/108 (2.8) 1.75 (0.36–8.63) 0.366
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Table 5  Adverse events of adjunctive cenobamate versus placebo according to treatment dose
Outcome or subgroup Number of studies 
[Reference]
Number of events/participants (%) I2 (%) Risk ratio (99% CI) p Value
CNB Placebo
CNB 100 mg/day
Any AE 1 [27] 70/108 (64.8) 76/108 (70.4) 0.92 (0.72–1.18) 0.384
Treatment-related AE 1 [27] 62/108 (57.4) 46/108 (42.6) 1.35 (0.94–1.93) 0.032
Any SAE 1 [27] 10/108 (9.3) 6/108 (5.6) 1.67 (0.46–6.01) 0.305
Somnolence 1 [27] 20/108 (18.5) 9/108 (8.3) 2.22 (0.84–5.88) 0.034
Dizziness 1 [27] 19/108 (17.6) 15/108 (13.9) 1.27 (0.56–2.87) 0.456
Headache 1 [27] 11/108 (10.2) 6/108 (5.6) 1.83 (0.52–6.46) 0.215
Nausea 1 [27] 7/108 (6.5) 1/108 (0.9) 7.00 (0.46–107.47) 0.066
Fatigue 1 [27] 13/108 (12.0) 9/108 (8.3) 1.44 (0.50–4.17) 0.372
Nystagmus 1 [27] 3/108 (2.8) 1/108 (0.9) 3.00 (0.16–57.52) 0.338
Balance disorder 1 [27] 3/108 (2.8) 0/108 (0.0) 7.00 (0.15–338.50) 0.196
Upper respiratory infection 1 [27] 3/108 (2.8) 6/108 (5.6) 0.50 (0.08–2.99) 0.318
Constipation 1 [27] 2/108 (1.9) 1/108 (0.9) 2.00 (0.09–45.99) 0.569
Vomiting 1 [27] 2/108 (1.9) 0/108 (0.0) 5.00 (0.09–266.30) 0.297
Ataxia 1 [27] 2/108 (1.9) 1/108 (0.9) 2.00 (0.09–45.99) 0.569
Dysarthria 1 [27] 2/108 (1.9) 0/108 (0.0) 5.00 (0.09–266.30) 0.297
Diplopia 1 [27] 8/108 (7.4) 2/108 (1.9) 4.00 (0.54–29.73) 0.075
Fall 1 [27] 2/108 (1.9) 6/108 (5.6) 0.33 (0.04–2.65) 0.172
Back pain 1 [27] 4/108 (3.7) 3/108 (2.8) 1.33 (0.19–9.24) 0.702
Vertigo 1 [27] 1/108 (0.9) 3/108 (2.8) 0.33 (0.02–6.39) 0.338
Decreased appetite 1 [27] 3/108 (2.8) 1/108 (0.9) 3.00 (0.16–57.52) 0.338
Gait disturbance 1 [27] 1/108 (0.9) 3/108 (2.8) 0.33 (0.02–6.39) 0.338
CNB 200 mg/day
Any AE 2 [26, 27] 170/223 (76.2) 145/217 (66.8) 0.0 1.14 (0.97–1.33) 0.034
Treatment-related AE 2 [26, 27] 139/223 (62.3) 96/217 (44.2) 0.0 1.41 (1.11–1.79) < 0.001
Any SAE 2 [26, 27] 6/223 (2.7) 10/217 (4.6) 0.0 0.59 (0.16–2.18) 0.295
Somnolence 2 [26, 27] 48/223 (21.5) 22/217 (10.1) 0.0 2.11 (1.14–3.90) 0.002
Dizziness 2 [26, 27] 47/223 (21.1) 33/217 (15.2) 0.0 1.38 (0.81–2.35) 0.115
Headache 2 [26, 27] 26/223 (11.7) 20/217 (9.2) 29.4 1.24 (0.59–2.58) 0.455
Nausea 2 [26, 27] 14/223 (6.3) 6/217 (2.8) 0.0 2.25 (0.66–7.72) 0.090
Fatigue 2 [26, 27] 31/223 (13.9) 16/217 (7.4) 0.0 1.89 (0.89–4.01) 0.030
Nystagmus 2 [26, 27] 15/223 (6.7) 1/217 (0.5) 0.0 7.49 (0.78–72.06) 0.022
Balance disorder 2 [26, 27] 11/223 (4.9) 1/217 (0.5) 0.0 7.26 (0.78–67.46) 0.022
Upper respiratory infection 2 [26, 27] 12/223 (5.4) 11/217 (5.1) 4.1 1.06 (0.36–3.11) 0.884
Constipation 2 [26, 27] 9/223 (4.0) 1/217 (0.5) 0.0 5.12 (0.50–52.26) 0.070
Vomiting 2 [26, 27] 9/223 (4.0) 2/217 (0.9) 0.0 3.51 (0.56–21.85) 0.077
Urinary tract infection 1 [26] 9/113 (8.0) 2/109 (1.8) 4.34 (0.60–31.56) 0.057
Tremor 1 [26] 7/113 (6.2) 3/109 (2.8) 2.25 (0.39–12.87) 0.231
Nasopharyngitis 1 [26] 7/113 (6.2) 1/109 (0.9) 6.75 (0.44–103.73) 0.072
Diarrhea 1 [26] 6/113 (5.3) 0/109 (0.0) 12.54 (0.29–541.21) 0.084
Anxiety 1 [26] 1/113 (0.9) 6/109 (5.5) 0.16 (0.01–2.54) 0.088
Ataxia 1 [27] 4/110 (3.6) 1/108 (0.9) 3.93 (0.23–68.48) 0.218
Dysarthria 1 [27] 3/110 (2.7) 0/108 (0.0) 6.87 (0.14–332.45) 0.200
Diplopia 1 [27] 11/110 (10.0) 2/108 (1.9) 5.40 (0.77–37.92) 0.026
Fall 1 [27] 4/110 (3.6) 6/108 (5.6) 0.66 (0.13–3.33) 0.502
Back pain 1 [27] 1/110 (0.9) 3/108 (2.8) 0.33 (0.02–6.28) 0.330
Vertigo 1 [27] 3/110 (2.7) 3/108 (2.8) 0.98 (0.12–7.81) 0.982
Decreased appetite 1 [27] 1/110 (0.9) 1/108 (0.9) 0.98 (0.03–36.88) 0.990
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cenobamate is crucial for managing the risk of allergic drug 
reactions and reducing the initial dose to 12.5 mg/day and 
slowing the up-titration rate to biweekly increments can sub-
stantially lower the likelihood of serious rash and DRESS. 
The “start-low and go-slow” strategy has been already 
shown to reduce the risk of immune-mediated hypersensi-
tivity reactions with other drugs, possibly by the develop-
ment of immune tolerance [32, 36]. Many more exposures 
are needed, however, to better assess the true safety profile 
of cenobamate, as a sample size of around 1350 patients 
can only rule out a 1/450 rate of DRESS [37]. The ongoing 
phase III study, open-label portions of the phase II RCTs 
[38, 39], as well as post-marketing surveillance will provide 
additional data to evaluate the incidence of rare AEs.
In both RCTs, cenobamate shortened the electrocar-
diogram QT interval in a dose-dependent manner. Similar 
findings were observed in a placebo-controlled QT study 
in healthy volunteers administered cenobamate [10]. This 
effect is likely due to the inhibition of the cardiac sodium 
channels and raises potential safety concerns in patients at 
risk for further QT-interval shortening. Accordingly, ceno-
bamate is contraindicated in patients with familial short QT 
syndrome, and caution is required in co-administration with 
other drugs known to reduce QT interval since a synergistic 
effect can occur [40, 41]. Finally, a trend of hyperkalemia 
was identified with the administration of cenobamate. The 
events of raised potassium values tended to be sporadic, and 
there were no critical outlier values associated with adverse 
cardiac AEs in controlled study data [15]. The sporadic 
occurrence leads to uncertainty about the causal association, 
and clinical chemistry monitoring is not strictly required 
[15].
4.2  Pharmacological Interactions
Earlier pharmacokinetic studies indicated that cenobamate 
can significantly increase plasma exposures of phenytoin and 
phenobarbital via inhibition of CYP2C19 [42]. Remarkably, 
the interim report from the ongoing phase III safety study 
provided dosing guidance for the real-world management of 
patients taking cenobamate and concomitant phenytoin or 
phenobarbital, who instead were excluded from the RCTs. 
In this study, which allows dose adjustment of concomitant 
ASMs based on the patient’s clinical condition and plasma 
Table 5  (continued)
Outcome or subgroup Number of studies 
[Reference]
Number of events/participants (%) I2 (%) Risk ratio (99% CI) p Value
CNB Placebo
Gait disturbance 1 [27] 6/110 (5.5) 3/108 (2.8) 1.96 (0.33–11.73) 0.331
CNB 400 mg/day
Any AE 1 [27] 110/111 (99.1) 76/108 (70.4) 1.28 (1.07–1.53) < 0.001
Treatment-related AE 1 [27] 92/111 (82.9) 46/108 (42.6) 1.95 (1.43–2.65) < 0.001
Any SAE 1 [27] 8/111 (7.2) 6/108 (5.6) 1.30 (0.34–4.99) 0.619
Somnolence 1 [27] 41/111 (36.9) 9/108 (8.3) 4.43 (1.84–10.71) < 0.001
Dizziness 1 [27] 37/111 (33.3) 15/108 (13.9) 2.40 (1.18–4.87) 0.001
Headache 1 [27] 12/111 (10.8) 6/108 (5.6) 1.95 (0.56–6.72) 0.167
Nausea 1 [27] 10/111 (9.0) 1/108 (0.9) 9.73 (0.67–141.77) 0.029
Fatigue 1 [27] 27/111 (24.3) 9/108 (8.3) 2.92 (1.15–7.39) 0.003
Nystagmus 1 [27] 7/111 (6.3) 1/108 (0.9) 6.81 (0.44–104.60) 0.070
Balance disorder 1 [27] 10/111 (9.0) 0/108 (0.0) 20.44 (0.50–836.92) 0.036
Upper respiratory infection 1 [27] 3/111 (2.7) 6/108 (5.6) 0.49 (0.08–2.91) 0.299
Constipation 1 [27] 10/111 (9.0) 1/108 (0.9) 9.73 (0.67–141.77) 0.029
Vomiting 1 [27] 6/111 (5.4) 0/108 (0.0) 12.65 (0.29–545.75) 0.082
Ataxia 1 [27] 7/111 (6.3) 1/108 (0.9) 6.81 (0.44–104.60) 0.070
Dysarthria 1 [27] 7/111 (6.3) 0/108 (0.0) 14.60 (0.34–618.40) 0.065
Diplopia 1 [27] 17/111 (15.3) 2/108 (1.9) 8.27 (1.25–54.95) 0.004
Fall 1 [27] 4/111 (3.6) 6/108 (5.6) 0.65 (0.13–3.30) 0.493
Back pain 1 [27] 6/111 (5.4) 3/108 (2.8) 1.95 (0.33–11.63) 0.337
Vertigo 1 [27] 6/111 (5.4) 3/108 (2.8) 1.95 (0.33–11.63) 0.337
Decreased appetite 1 [27] 6/111 (5.4) 1/108 (0.9) 5.84 (0.37–92.27) 0.100
Gait disturbance 1 [27] 9/111 (8.1) 3/108 (2.8) 2.92 (0.54–15.69) 0.101
AE adverse event, CI confidence interval, CNB cenobamate, SAE serious adverse event
Risk ratios are from a fixed-effects model; significance set at p < 0.01
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levels, around 45 and 30% of patients taking phenytoin and 
phenobarbital had their doses decreased [35]. At the end 
of the titration, the mean plasma levels of phenytoin and 
phenobarbital were generally comparable to those obtained 
before the start of cenobamate, suggesting that periodic dose 
reductions of 25–33% in response to AEs can be effective 
to maintain stable plasma levels [35]. In the same way, a 
reduction in dosage of clobazam should be considered, as 
clinically appropriate, to counteract the increase in plasma 
concentrations of desmethylclobazam, the active metabo-
lite of clobazam, that occurs when cenobamate is concomi-
tantly prescribed [10]. Cenobamate has been also shown to 
decrease the plasma exposure to carbamazepine by around 
25% through the induction of CYP3A4 [42], and carbamaz-
epine dose adjustment may be necessary when these drugs 
are used in combination. Similarly, an increase in the dosage 
of lamotrigine may be required when cenobamate is added 
to the therapeutic drug regimen [10].
4.3  Strengths and Limitations
This systematic review with meta-analysis is a compre-
hensive synthesis of the efficacy and safety of adjunctive 
cenobamate in adult patients with focal-onset seizures. 
Efficacy and safety analyses were also performed accord-
ing to cenobamate daily dosages and the estimates of sei-
zure responses during the maintenance phase could reflect 
steady-state drug levels at the target dose more accurately 
than data referring to the entire treatment period, includ-
ing the titration phase. Nonetheless, different shortcomings 
need to be acknowledged. Only two trials met the eligibility 
criteria, a single pharmaceutical company funded both of 
them, and the efficacy of cenobamate at the highest dose 
was explored in one single study. The meta-analysis inher-
ited the general limitations and assumptions of the RCTs of 
adjunctive ASMs, including the short duration of the main-
tenance phase, the highly selected inclusion and exclusion 
criteria for enrollment, and the potential effect of concomi-
tant medications whose dosage must be kept unchanged 
throughout the double-blind period. Although cenobamate 
demonstrated a broad spectrum of activity and was effica-
cious in several animal models of epilepsy, including the 
maximal electroshock seizure test, seizures produced by 
picrotoxin and pentylenetetrazol, the hippocampal kindled 
rat model, and the mouse 6-Hz psychomotor seizure model 
[30], this review focused only on the use of cenobamate in 
focal epilepsy. In this regard, ongoing phase III trials are 
recruiting patients with primary generalized tonic–clonic 
seizures (NCT03678753, NCT03961568). Likewise, this 
meta-analysis cannot provide information about the efficacy 
and tolerability of cenobamate as monotherapy, the safety of 
cenobamate during pregnancy and lactation, or the quality 
of life or health economic outcomes.
5  Conclusions
Adjunctive cenobamate appears an effective treatment 
option for focal-onset seizures. Despite the development of 
many ASMs in the past decades, little has changed in the rate 
of patients who can achieve seizure freedom. In this con-
text, trial data suggest that cenobamate stands out against the 
compounds approved in the last 25 years and brings promise 
for patients who have difficult-to-control seizures, mainly 
if the higher dosages can be tolerated [30, 37]. As cenoba-
mate seizure-freedom rates appear substantially higher than 
those of other ASMs, it will be important to make sure that 
patients tolerate the introduction of this drug into the exist-
ing therapeutic regimen. Special caution and slower titration 
or stepwise tapering off should be considered in patients on 
other sodium channel blockers to increase tolerability and 
reduce the risk of treatment failure due to AEs. Real-world 
evidence will complement and further clarify the true thera-
peutic potentialities and clinical relevance of this newest 
anti-seizure drug.
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